The roles of M30 and M65 in the assessment of treatment response and prognosis in patients with non-small cell lung cancer, who receive neoadjuvant treatment.

Coskun, BELKIS; Dizdar, Oguzhan; Korkmaz, Seniz; Ulukaya, Engin; EVRENSEL, TÜRKKAN

doi:10.5114/wo.2019.91539

The roles of M30 and M65 in the assessment of treatment response and prognosis in patients with non-small cell lung cancer, who receive neoadjuvant treatment.

Coskun B. N., Dizdar O. S., Korkmaz S., Ulukaya E., EVRENSEL T.

Contemporary oncology (Poznan, Poland), cilt.23, sa.4, ss.208-213, 2019 (Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 23 Sayı: 4
Basım Tarihi: 2019
Doi Numarası: 10.5114/wo.2019.91539
Dergi Adı: Contemporary oncology (Poznan, Poland)
Derginin Tarandığı İndeksler: Scopus
Sayfa Sayıları: ss.208-213
Bursa Uludağ Üniversitesi Adresli: Evet

Özet

Aim of the study: To investigate the efficacy of evaluating prognosis and response to lung cancer treatment using M30 and M65 antigens, which are indicators of necrosis.